Ouki surfaces proprietary drug repurposing intelligence across 23 disease conditions. Available to qualifying organisations under commercial agreement.
Over 4,000 medical research papers are published daily. No team can monitor the full breadth of published science across disease boundaries. Significant connections remain undiscovered.
FDA-approved drugs with established safety profiles can be repurposed for new indications — bypassing years of safety testing and dramatically compressing development timelines and costs.
Ouki operates continuously across 23 disease conditions, identifying mechanistically grounded drug repurposing hypotheses that cross-disciplinary research has not yet explored.
Each finding identifies a specific FDA-approved drug, the proposed mechanism in a new indication, and the precise gap in existing research. Available under commercial agreement.
Basophil Activation Test-Adaptive Protocol
A protocol using a validated immune readiness test to dynamically guide when doses are escalated, held, or reduced. No prior trial has tested this adaptive approach.
September 2026Pharmacokinetic Optimisation
A biological mechanism in adolescent males predicted to reduce drug exposure below therapeutic levels during puberty. Two independent cohorts support the sex-specific failure signal.
September 2026Repurposed Short-Chain Fatty Acid Supplement
A naturally occurring compound shown in preclinical models to directly reverse tissue changes in a serious lupus complication. Low-toxicity, widely available, no clinical trial has ever tested it for this application.
September 2026Ouki generates research hypotheses, not medical advice. All findings require validation by qualified medical researchers through proper clinical studies. This platform is designed as a research acceleration tool for the scientific community.
Ouki's drug repurposing intelligence is available to qualifying pharmaceutical companies, biotech firms, and research institutions. All access is subject to NDA and commercial agreement.
Request Access →